Neratinib-Plus-Cetuximab in Quadruple-WT (<i>KRAS, NRAS, BRAF, PIK3CA</i>) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study

Jacobs, Samuel A.; Lee, James J.; George, Thomas J.; Wade, James L.; Stella, Philip J.; Wang, Ding; Sama, Ashwin R.; Piette, Fanny; Pogue–Geile, Katherine L.; Kim, Rim S.; Gavin, Patrick G.; Lipchik, Corey; Feng, Huichen; Wang, Ying; Finnigan, Melanie; Kiesel, Brian F.; Beumer, Jan H.; Wolmark, Norman; Lucas, Peter C.; Allegra, Carmen J.; Srinivasan, Ashok

doi:10.1158/1078-0432.ccr-20-1831

Cited by 18 publications

(20 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In two large clinical studies, trastuzumab and lapatinib/pertuzumab combinations showed good activity and tolerability in EGFR-resistant HER2-positive mCRC [ 74 , 75 ]. However, data from a recently published Phase Ib clinical study suggest that neratinib-plus-cetuximab did not show an objective response in quadruple-WT (KRAS, NRAS, BRAF and PIK3CA) mCRC resistant to cetuximab or panitumumab [ 73 ].…”

Section: Aberrant Activations Of Alternative Receptorsmentioning

confidence: 99%

Drug Resistance in Colorectal Cancer: From Mechanism to Clinic

Wang

Shen

Chen

et al. 2022

Cancers

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the leading causes of death worldwide. The 5-year survival rate is 90% for patients with early CRC, 70% for patients with locally advanced CRC, and 15% for patients with metastatic CRC (mCRC). In fact, most CRC patients are at an advanced stage at the time of diagnosis. Although chemotherapy, molecularly targeted therapy and immunotherapy have significantly improved patient survival, some patients are initially insensitive to these drugs or initially sensitive but quickly become insensitive, and the emergence of such primary and secondary drug resistance is a significant clinical challenge. The most direct cause of resistance is the aberrant anti-tumor drug metabolism, transportation or target. With more in-depth research, it is found that cell death pathways, carcinogenic signals, compensation feedback loop signal pathways and tumor immune microenvironment also play essential roles in the drug resistance mechanism. Here, we assess the current major mechanisms of CRC resistance and describe potential therapeutic interventions.

show abstract

Section: Aberrant Activations Of Alternative Receptorsmentioning

confidence: 99%

Drug Resistance in Colorectal Cancer: From Mechanism to Clinic

Wang

Shen

Chen

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Jacobs et al reported the results of a phase Ib clinical trial involving 11 patients with RAS/BRAF/PIK3CA WT; ERRB2-positive tumors were treated with neratinib and cetuximab. However, it did not show responses: seven received stable disease, four of whom had ERBB2 amplification either in the primary tumor or the enrolment biopsy [ 77 ].…”

Section: Clinical Trials For Patients With Erbb2-positive Mcrcmentioning

confidence: 99%

Precision Medicine in Metastatic Colorectal Cancer: Targeting ERBB2 (HER-2) Oncogene

Torres-Jiménez

Esteban-Villarrubia²,

Ferreiro-Monteagudo³

2022

Cancers

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the third most common cancer in terms of incidence rate in adults and the second most common cause of cancer-related death in Europe. The treatment of metastatic CRC (mCRC) is based on the use of chemotherapy, anti-vascular endothelial growth factor (VEGF), and anti-epidermal growth factor receptor (EGFR) for RAS wild-type tumors. Precision medicine tries to identify molecular alterations that could be treated with targeted therapies. ERBB2 amplification (also known as HER-2) has been identified in 2–3% of patients with mCRC, but there are currently no approved ERBB2-targeted therapies for mCRC. The purpose of this review is to describe the molecular structure of ERBB2, clinical features of these patients, diagnosis of ERBB2 alterations, and the most relevant clinical trials with ERBB2-targeted therapies in mCRC.

show abstract

“…Only one in 7 patients had dose-limiting toxicity (G3 diarrhoea), although 67% had G3 AEs. Drug-related AEs of special interest were diarrhoea, rash and elevated transaminases [43].…”

Section: Dual Monoclonal Antibodiesmentioning

confidence: 99%

Mind the target: human epidermal growth factor receptor 2 in colorectal cancer

Saúde-Conde

Rasschaert

Bregni

et al. 2022

Current Opinion in Oncology

View full text Add to dashboard Cite

Purpose of reviewIn this article, we briefly summarise the current knowledge about human epidermal growth factor receptor 2 (HER2) alterations in colorectal cancer (CRC) and provide an overview of the latest published evidence especially regarding standardisation of detection methods/diagnostic criteria, prognostication, prediction and targeted treatments.Recent findingsOver the last 18 months, the results of many studies have been presented confirming the therapeutic potential of established anti-HER2 agents either as a monotherapy or in combination, as well as new anti-HER2 agents like antibody-drug-conjugates and tyrosine kinase inhibitors. Also, we have seen confirmation of the utility of liquid biopsy and ctDNA analyses as tool for HER2 detection and patient selection.SummaryDespite concerning only 5% of metastatic CRC, HER2 represents a valuable target for emerging anti-HER2 therapies that might significantly improve the outcome of these patients. Standardising HER2 detection methods/diagnostic criteria, and producing high-quality, randomised evidence are the next challenges to meet the standards of regulatory authorities and ultimately have anti-HER2 agents available for use in routine practice.

show abstract

Neratinib-Plus-Cetuximab in Quadruple-WT (KRAS, NRAS, BRAF, PIK3CA) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study

Cited by 18 publications

References 41 publications

Drug Resistance in Colorectal Cancer: From Mechanism to Clinic

Drug Resistance in Colorectal Cancer: From Mechanism to Clinic

Precision Medicine in Metastatic Colorectal Cancer: Targeting ERBB2 (HER-2) Oncogene

Mind the target: human epidermal growth factor receptor 2 in colorectal cancer

Contact Info

Product

Resources

About